NeuroSearch announces revised financial calendar for 2007 and financial calendar

Not for release, publication or distribution in Australia, Canada, Japan or the
United States. This announcement does not constitute an offer to sell or the
solicitation of an offer to buy the securities of NeuroSearch A/S (the
“Securities”) in Australia, Canada, Japan or the United States or in any other
jurisdiction. Securities may not be offered or sold in the United States absent
registration or an exemption from registration under the U.S. Securities Act of
1933, as amended. The issuer of the Securities has not registered, and does not
intend to register, any portion of the Offering in the United States, and does
not intend to conduct a public offering of the Securities in the United States. 


Announcement                                                                    


NeuroSearch announces revised financial calendar for 2007 and financial calendar
for 2008                                                                        

Revised financial calendar 2007                                                 
NeuroSearch plans to release its third quarter 2007 report on 28 November 2007. 

Financial calendar 2008                                                         
NeuroSearchs financial calendar for 2008 is as follows:                         

5 March 2008: 	2007 annual report                                               
30 April 2008: 	Annual general meeting and first quarter 2008 report            
27 August 2008: 	2008 half year report                                          
19 November 2008: 	Third quarter 2008 report                                    


Asger Aamund                                                                    
Chairman of the Board                                                           



--------------------------------------------------------------------------------
| Contacts:                                 | Telephone:                       |
--------------------------------------------------------------------------------
| Flemming Pedersen, CEO                    | +45 4460 8214 or +45 2148 0118   |
--------------------------------------------------------------------------------
| Hanne Leth Hillman, Vice President,       | +45 4460 8212 or +45 4017 5103   |
| Director of Investor Relations &          |                                  |
| Corporate Communications                  |                                  |
--------------------------------------------------------------------------------



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the Company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD   
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in             
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder
and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the        
treatment of various CNS diseases - both (Phase I) in collaboration with Abbott.
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates   
and holds equity interests in several biotech companies.